Bioceres Crop Solutions Statistics
Total Valuation
BIOX has a market cap or net worth of $425.83 million. The enterprise value is $661.51 million.
Important Dates
The next estimated earnings date is Thursday, February 6, 2025, after market close.
| Earnings Date | Feb 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BIOX has 62.85 million shares outstanding. The number of shares has increased by 0.04% in one year.
| Current Share Class | 62.85M |
| Shares Outstanding | 62.85M |
| Shares Change (YoY) | +0.04% |
| Shares Change (QoQ) | -1.49% |
| Owned by Insiders (%) | 1.42% |
| Owned by Institutions (%) | 16.21% |
| Float | 31.94M |
Valuation Ratios
The trailing PE ratio is 295.45 and the forward PE ratio is 17.81. BIOX's PEG ratio is 1.48.
| PE Ratio | 295.45 |
| Forward PE | 17.81 |
| PS Ratio | 1.00 |
| Forward PS | 0.86 |
| PB Ratio | 1.42 |
| P/TBV Ratio | 20.10 |
| P/FCF Ratio | 17.28 |
| P/OCF Ratio | 13.47 |
| PEG Ratio | 1.48 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 11.42, with an EV/FCF ratio of 26.40.
| EV / Earnings | 451.31 |
| EV / Sales | 1.50 |
| EV / EBITDA | 11.42 |
| EV / EBIT | 16.56 |
| EV / FCF | 26.40 |
Financial Position
The company has a current ratio of 1.27, with a Debt / Equity ratio of 0.77.
| Current Ratio | 1.27 |
| Quick Ratio | 0.82 |
| Debt / Equity | 0.77 |
| Debt / EBITDA | 4.35 |
| Debt / FCF | 10.64 |
| Interest Coverage | 1.73 |
Financial Efficiency
Return on equity (ROE) is 0.81% and return on invested capital (ROIC) is 4.21%.
| Return on Equity (ROE) | 0.81% |
| Return on Assets (ROA) | 3.03% |
| Return on Capital (ROIC) | 4.21% |
| Revenue Per Employee | $1.13M |
| Profits Per Employee | $3,768 |
| Employee Count | 389 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 2.05 |
Taxes
In the past 12 months, BIOX has paid $2.08 million in taxes.
| Income Tax | 2.08M |
| Effective Tax Rate | 43.22% |
Stock Price Statistics
The stock price has decreased by -48.63% in the last 52 weeks. The beta is 0.53, so BIOX's price volatility has been lower than the market average.
| Beta (5Y) | 0.53 |
| 52-Week Price Change | -48.63% |
| 50-Day Moving Average | 6.61 |
| 200-Day Moving Average | 9.25 |
| Relative Strength Index (RSI) | 54.93 |
| Average Volume (20 Days) | 188,076 |
Short Selling Information
| Short Interest | 717,489 |
| Short Previous Month | 648,434 |
| Short % of Shares Out | 1.14% |
| Short % of Float | 2.25% |
| Short Ratio (days to cover) | 3.82 |
Income Statement
In the last 12 months, BIOX had revenue of $441.27 million and earned $1.47 million in profits. Earnings per share was $0.02.
| Revenue | 441.27M |
| Gross Profit | 175.96M |
| Operating Income | 39.94M |
| Pretax Income | 9.30M |
| Net Income | 1.47M |
| EBITDA | 57.92M |
| EBIT | 39.94M |
| Earnings Per Share (EPS) | $0.02 |
Full Income StatementBalance Sheet
The company has $38.18 million in cash and $266.63 million in debt, giving a net cash position of -$228.45 million or -$3.63 per share.
| Cash & Cash Equivalents | 38.18M |
| Total Debt | 266.63M |
| Net Cash | -228.45M |
| Net Cash Per Share | -$3.63 |
| Equity (Book Value) | 346.02M |
| Book Value Per Share | 4.92 |
| Working Capital | 81.23M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $32.14 million and capital expenditures -$7.08 million, giving a free cash flow of $25.06 million.
| Operating Cash Flow | 32.14M |
| Capital Expenditures | -7.08M |
| Free Cash Flow | 25.06M |
| FCF Per Share | $0.40 |
Full Cash Flow StatementMargins
Gross margin is 39.88%, with operating and profit margins of 9.05% and 0.33%.
| Gross Margin | 39.88% |
| Operating Margin | 9.05% |
| Pretax Margin | 1.09% |
| Profit Margin | 0.33% |
| EBITDA Margin | 13.12% |
| EBIT Margin | 9.05% |
| FCF Margin | 5.68% |
Dividends & Yields
BIOX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.04% |
| Shareholder Yield | -0.04% |
| Earnings Yield | 0.34% |
| FCF Yield | 5.79% |
Analyst Forecast
The average price target for BIOX is $13.90, which is 105.17% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $13.90 |
| Price Target Difference | 105.17% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 8.93% |
| EPS Growth Forecast (5Y) | 88.43% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BIOX has an Altman Z-Score of 1.7 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.7 |
| Piotroski F-Score | 6 |